TPP-dendrimer nanocarriers for siRNA delivery to the pulmonary epithelium and their dry powder and metered-dose inhaler formulations

Bielski, Elizabeth; Zhong, Qian; Mirza, Hamad; Brown, Matthew; Molla, Ashura; Carvajal, Teresa; Rocha, Sandro R. P. da

doi:10.1016/j.ijpharm.2017.05.046

Cited by 55 publications

(19 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even so, the exploration has been made of dendrimers for various pulmonary diseases, exploring the treatment of asthma by loading dendrimers with beclometasone dipropionate and studying the possibility of nebulizing the loaded dendrimers [ 149 ], and systemic delivery of proteins and peptides through the pulmonary route [ 150 ]. Also, surface-modified dendrimers have been studied in gene therapy with promising results in vitro experiments [ 151 ]. Kandeel et al [ 152 ] used cationic and anionic dendrimers with hydroxyl, carboxyl, and succinamic acid terminated PAMAMs as terminals groups to prevent the plaque formation of MERS-CoV, obtaining a diminution of about 40% with anionic dendrimers.…”

Section: Nanostructures On Respiratory Therapymentioning

confidence: 99%

Nanostructures for drug delivery in respiratory diseases therapeutics: Revision of current trends and its comparative analysis

Ibarra-Sánchez

Gámez-Méndez

Martínez-Ruiz

et al. 2022

Journal of Drug Delivery Science and Technology

View full text Add to dashboard Cite

Section: Nanostructures On Respiratory Therapymentioning

confidence: 99%

Nanostructures for drug delivery in respiratory diseases therapeutics: Revision of current trends and its comparative analysis

Ibarra-Sánchez

Gámez-Méndez

Martínez-Ruiz

et al. 2022

Journal of Drug Delivery Science and Technology

View full text Add to dashboard Cite

“…Freeze-dried pulmonary surfactant (Curosurf ® )-coated nanogels could also deliver therapeutic siRNAs to the lungs via a nebulizer [ 250 , 251 ]. Another nanocarrier made of triphenyl phosphonium (TPP)-modified generation 4 poly(amidoamine) (PAMAM) dendrimer (G4NH2-TPP) can be made into inhalation preparations after loading siRNA [ 252 ]. Thus, local administration of siRNA therapeutics to the lungs can effectively combat lung infections, lung cancer, cystic fibrosis, asthma, and many other diseases of the respiratory system [ 253 ].…”

Section: Challenges Of Local Delivery Of Np-sirnas—the Importance Of ...mentioning

confidence: 99%

Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract

Zhang

Almazi

Ong

et al. 2022

IJMS

View full text Add to dashboard Cite

Since December 2019, a pandemic of COVID-19 disease, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has rapidly spread across the globe. At present, the Food and Drug Administration (FDA) has issued emergency approval for the use of some antiviral drugs. However, these drugs still have limitations in the specific treatment of COVID-19, and as such, new treatment strategies urgently need to be developed. RNA-interference-based gene therapy provides a tractable target for antiviral treatment. Ensuring cell-specific targeted delivery is important to the success of gene therapy. The use of nanoparticles (NPs) as carriers for the delivery of small interfering RNA (siRNAs) to specific tissues or organs of the human body could play a crucial role in the specific therapy of severe respiratory infections, such as COVID-19. In this review, we describe a variety of novel nanocarriers, such as lipid NPs, star polymer NPs, and glycogen NPs, and summarize the pre-clinical/clinical progress of these nanoparticle platforms in siRNA delivery. We also discuss the application of various NP-capsulated siRNA as therapeutics for SARS-CoV-2 infection, the challenges with targeting these therapeutics to local delivery in the lung, and various inhalation devices used for therapeutic administration. We also discuss currently available animal models that are used for preclinical assessment of RNA-interference-based gene therapy. Advances in this field have the potential for antiviral treatments of COVID-19 disease and could be adapted to treat a range of respiratory diseases.

show abstract

“…More importantly, tertiary amine groups in PAMAM dendrimers' interior have a pH buffering ability, which renders the endosomal escape of the complexes. 132,133 Furthermore, PAMAM dendrimers are relatively nonimmunogenic, thus reducing the safety risks of nonviral vectors in gene delivery. Because of these properties, PAMAM dendrimers are safe and efficient alternatives to nonviral gene vectors for cancer therapy.…”

Section: Polymeric Npsmentioning

confidence: 99%

“…Second, these polymers' cationic surface makes it easy to condense pDNA or siRNA molecules into PAMAM‐pDNA/siRNA complexes. More importantly, tertiary amine groups in PAMAM dendrimers' interior have a pH buffering ability, which renders the endosomal escape of the complexes 132,133 . Furthermore, PAMAM dendrimers are relatively nonimmunogenic, thus reducing the safety risks of nonviral vectors in gene delivery.…”

Section: Use Of Nanomaterials In Colon Cancer Diagnosis and Treatmentmentioning

confidence: 99%

Trends in targeted delivery of nanomaterials in colon cancer diagnosis and treatment

Khan

Albalawi

Pottoo

2021

Medicinal Research Reviews

View full text Add to dashboard Cite

Colon cancer is an adenocarcinoma, which subsequently develops into malignant tumors, if not treated properly. The current colon cancer therapy mainly revolves around chemotherapy, radiotherapy and surgery, but the search continues for more effective interventions. With the advancement of nanoparticles (NPs), it is now possible to diagnose and treat colon cancers with different types, shapes, and sizes of NPs. Nanoformulations such as quantum dots, iron oxide, polymeric NPs, dendrimers, polypeptides, gold NPs, silver NPs, platinum NPs, and cerium oxide have been either extensively used alone or in combination with other nanomaterials or drugs in colon cancer diagnosis, and treatments. These nanoformulations possess high biocompatibility and bioavailability, which makes them the most suitable candidates for cancer treatment. The size and shape of NPs are critical to achieving an effective drug delivery in cancer treatment and diagnosis. Most NPs currently are under different testing phases (in vitro, preclinical, and clinical), whereas some of them have been approved for therapeutic applications. We have

show abstract

TPP-dendrimer nanocarriers for siRNA delivery to the pulmonary epithelium and their dry powder and metered-dose inhaler formulations

Cited by 55 publications

References 63 publications

Nanostructures for drug delivery in respiratory diseases therapeutics: Revision of current trends and its comparative analysis

Nanostructures for drug delivery in respiratory diseases therapeutics: Revision of current trends and its comparative analysis

Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract

Trends in targeted delivery of nanomaterials in colon cancer diagnosis and treatment

Contact Info

Product

Resources

About